4.5 Article

Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials

Related references

Note: Only part of the references are listed.
Article Oncology

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer et al.

Summary: The PALLAS trial investigated whether adding 2 years of palbociclib to adjuvant endocrine therapy could improve invasive disease-free survival in early-stage hormone-receptor-positive, HER2-negative breast cancer patients, but the results showed no significant benefit. The trial was then discontinued based on the lack of efficacy observed during the planned second interim analysis.

LANCET ONCOLOGY (2021)

Article Oncology

Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments

Richard A. Anderson et al.

Summary: Cancer treatment can have adverse effects on reproductive function, leading to loss of fertility, sexual desire and function, and hormone deficiency. Proactive assessment and counseling on the impact of treatment on reproductive function are essential for patient mental health and quality of life. Providing accurate information and fertility preservation options can potentially influence treatment decisions and improve patient outcomes.

EUROPEAN JOURNAL OF CANCER (2021)

Article Oncology

Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0

Sara M. Tolaney et al.

Summary: This study assessed the adherence of primary efficacy end points in adjuvant breast cancer trials to standardized definitions. Simulation modeling revealed the impact of excluding second nonbreast primary cancers on outcomes, leading to the recommendation of adding invasive breast cancer-free survival as an additional end point.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Article Oncology

Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation

Wanyuan Cui et al.

Summary: The impact of pharmacologic interventions on ovarian function is infrequently assessed in phase III breast cancer (neo)adjuvant trials that include premenopausal women. Only a small percentage of trials collect postintervention data related to ovarian function, indicating a need for more attention to this important aspect in clinical trial design.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

Article Medicine, General & Internal

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N. J. Tutt et al.

Summary: In patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, adjuvant olaparib after completion of local treatment and neoadjuvant or adjuvant chemotherapy was associated with significantly longer survival free of invasive or distant disease than placebo. Olaparib had limited effects on global patient-reported quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Oncology

Effective delivery of Complex Innovative Design (CID) cancer trials-A consensus statement

Sarah P. Blagden et al.

BRITISH JOURNAL OF CANCER (2020)

Article Medicine, General & Internal

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Oncology

Issues with Fertility in Young Women with Breast Cancer

Nicole Christian et al.

CURRENT ONCOLOGY REPORTS (2019)

Review Oncology

Barriers and facilitators towards fertility preservation care for cancer patients: a meta-synthesis

N. Panagiotopoulou et al.

EUROPEAN JOURNAL OF CANCER CARE (2018)

Article Oncology

Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update

Kutluk Oktay et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Article Oncology

Adolescent and Young Adult Oncology, Version 2.2018

Peter F. Coccia et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)

Article Medicine, General & Internal

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

P. A. Francis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

Gunter von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Oncology

ESMO-Magnitude of Clinical Benefit Scale version 1.1

N. I. Cherny et al.

ANNALS OF ONCOLOGY (2017)

Article Obstetrics & Gynecology

ESHRE Guideline: management of women with premature ovarian insufficiency

L. Webber et al.

HUMAN REPRODUCTION (2016)

Article Health Care Sciences & Services

PRO development: rigorous qualitative research as the crucial foundation

Kathryn Eilene Lasch et al.

QUALITY OF LIFE RESEARCH (2010)

Letter Oncology

Measuring the impact of chemotherapy on fertility in women with breast cancer

Kutluk Oktay et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Article Health Care Sciences & Services

Patient and clinician collaboration in the design of a national randomized breast cancer trial

J Marsden et al.

HEALTH EXPECTATIONS (2004)